Three studies presented at the American Society of Hematology (ASH) 58th Annual Meeting held in San Diego, California, US highlight the use of chimeric antigen receptor (CAR) T cell therapy for the treatment of refractory adult and paediatric lymphoma and leukaemia.
Findings from a phase III trial show that the anti-CD30 antibody-drug conjugate, brentuximab vedotin (BV), is superior to methotrexate or bexarotene in the efficacy endpoint of overall response rate (ORR) lasting ≥4 months in the treatment of cutaneous T cell lymphoma (CTCL).
Cancer patients who have undergone successful treatment may have increased risk of developing therapy-related myeloid neoplasms (t-MNs), a fatal form of secondary malignancy, even after years of successful treatment, according to a recent study presented at the ASH 58th Annual Meeting in San Diego, California, US.
Lenalidomide maintenance therapy reduces the risk of progression by more than 80 percent in patients with high-risk chronic lymphocytic leukaemia (CLL) who responded to first-line chemoimmunotherapy, interim results of the phase III CLL M1 study have shown.
Obinutuzumab reduces the risk of disease progression by about one-third in patients with advanced follicular lymphoma (FL) compared with rituximab, interim results of the phase III GALLIUM study have shown.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Oncology - Malaysia digital copy today!
Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Circulating miR-155 may be potentially used as a diagnostic and therapeutic monitoring marker in breast cancer, suggests an Indonesian study presented at the 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).